Current Size: 100%


Richard Moriggl receives funding to identify novel inhibitors of STAT3

The FFG has now decided to fund a new project entitled "Identification of novel STAT3/5 inhibitors to interfere with the oncogenic activities of STATs in hematopoietic cancer" in collaboration of Prof. Richard Moriggl of the LBI-CR and Prof. Patrick Gunning of the University Toronto, which aims to identify new compounds blocking STAT function in cancer. STATs are hyper activated in many solid and hematopoietic cancers due to mutations in upstream kinases or point mutations in conserved domains of STAT proteins.

DOC fellowship of Austrian Academy of Sciences for Luisa Schmidt

Luisa Schmidt, PhD student in the group of Florian Grebien has received a prestigious DOC fellowship from the Austrian Academy of Sciences. She studies the contribution of the transcription factor C/EBPα to acute myeloid leukemia and is particularly interested in how disease development is influenced by the epigenomic landscape and super-enhancers. Her project aims to elucidate the molecular functions of the leukemia-associated, truncated isoform C/EBPα p30 by exploring its influence on the epigenome.

External Evaluation strongly endorses LBI-CR research strategy

The Ludwig Boltzmann Gesellschaft (LBG) invited with Prof. Dr. Gerard Evan (Head of Department of Biochemistry, University of Cambridge, UK) (chair), Prof. Dr. Aly Karsan (Department of Pathology and Laboratory Medicine, University of  British Columbia; Medical Director, Centre for Clinical Genomics, Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada)  Prof. Dr.

Annual Meeting 2015 in Seggau

An entire decade of exciting research at the LBI-CR has passed since the institute was founded in September 2005. We generated significant research output as measured by publications, attraction of third party money, and seeing former members successfully embarking on international careers. This achievement was celebrated in November 2015 with a scientific meeting, which brought together some outstanding researchers, who have contributed to the success of the institute with their advice, support or collaboration.

Scientists launch 23 million euro project to develop HIV-vaccine

A new 23 million euro initiative to accelerate the search for an effective HIV vaccine begins in November 2015.

Financed by the European Commission, the European AIDS Vaccine Initiative (EAVI2020) is a focused effort to develop protective and therapeutic HIV vaccines bringing together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA, including the LBI-CR.